Eli Lilly, Boehringer Ingelheim provide update from EMPERIAL trials
Boehringer Ingelheim and Eli Lilly announced results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to functional endpoints with Jardiance in adults with chronic heart failure with reduced and preserved ejection fraction, respectively. In both trials, there was no significant change from baseline to week 12 in exercise ability with Jardiance versus placebo, as measured by the six-minute walk test, which was the primary endpoint of the studies. The safety profile seen in the EMPERIAL trials was similar to the currently known safety profile of Jardiance and no new safety risks were identified. The EMPERIAL trials, which included people with and without diabetes, deliver novel safety data for Jardiance in non-diabetic patients with heart failure. In addition, EMPERIAL-Preserved is the first trial to deliver safety data for Jardiance in heart failure with preserved ejection fraction. Full results from the EMPERIAL trials will be shared in 2020.